NewAmsterdam Pharma Company N.V. NAMSW
Nov 4, 2026, 10:04 AM EST
- YTD
- -59.78%
- 1 year
- -62.78%
- Market cap
- 2.33B
- Revenue (ttm)
- 7.12M
- YTD return
- -59.78%
- 1-year return
- -62.78%
- Volume
- 812
- Avg volume
- 1.47K
- Open
- 24.41
- Previous close
- 9.50
- Day's range
- 9.25 – 9.25
- 52-week range
- 8.25 – 30.45
- Beta
- 0.14
- Earnings date
- Nov 11, 2026
2Y -0.30 (-3.06%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.77
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -80.70%
- Free cash flow
- -45.36M
- Total cash
- 633.85M
- Total debt
- 82.00K
- Return on equity
- -36.81%
- Short % of float
- 0.00%
- 50-day average
- 11.93
- 200-day average
- 18.92
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | -0.49491 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | -0.47702 | -0.52 | -0.04 | -9.01% |
| May 7, 2026 | Mar 31, 2026 | -0.45897 | -0.40 | +0.06 | +12.85% |
| Feb 18, 2026 | Dec 31, 2025 | -0.45375 | -0.62 | -0.17 | -36.64% |
| Nov 5, 2025 | Sep 30, 2025 | -0.39095 | -0.60508 | -0.21 | -54.77% |
| Aug 6, 2025 | Jun 30, 2025 | -0.46317 | -0.18402 | +0.28 | +60.27% |
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
- Country
- Netherlands
- Website
- newamsterdampharma.com
News
Your note
Sign in to keep a note on NAMSW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 10.88% | 500,333 | 4.75M | Jun 29, 2026 |
| RA Capital Management, L.P. | 7.25% | 333,333 | 3.17M | Jun 29, 2026 |
| Affinity Asset Advisors, Llc | 5.33% | 245,000 | 2.33M | Jun 29, 2026 |
| Bain Capital Life Sciences Investors, LLC | 2.17% | 99,999 | 949.99K | Jun 29, 2026 |
| Deerfield Management Company, L.P | 2.02% | 92,787 | 881.48K | Jun 29, 2026 |
| Wolverine Asset Management, LLC | 0.38% | 17,464 | 165.91K | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| JNL Series Trust-JNL/Westchester Capital Event Driven Fund | 0.14% | 6,630 | 62.98K | Dec 30, 2023 |